Your browser doesn't support javascript.
loading
The contingent use of cell-free fetal DNA for prenatal screening of trisomies 21, 18, 13 in pregnant women within a national health service: A budget impact analysis.
Prefumo, Federico; Paolini, Davide; Speranza, Giulia; Palmisano, Marilena; Dionisi, Matteo; Camurri, Lamberto.
Afiliação
  • Prefumo F; ASST degli Spedali Civili di Brescia, Brescia, Italy.
  • Paolini D; Medical & Market Access Department, Roche Diagnostics, Monza, Italy.
  • Speranza G; Medical & Market Access Department, Roche Diagnostics, Monza, Italy.
  • Palmisano M; Medical & Market Access Department, Roche Diagnostics, Monza, Italy.
  • Dionisi M; Medical & Market Access Department, Roche Diagnostics, Monza, Italy.
  • Camurri L; Medi Saluser, Parma, Italy.
PLoS One ; 14(6): e0218166, 2019.
Article em En | MEDLINE | ID: mdl-31188879
OBJECTIVE: Non-invasive prenatal testing (NIPT) based on cell-free fetal DNA (cffDNA) is highly accurate in the detection of common fetal autosomal trisomies. Aim of this project was to investigate short-term costs and clinical outcomes of the contingent use of cffDNA for prenatal screening of trisomies 21, 18, 13 within a national health service (NHS). METHODS: An economic analysis was developed from the perspective of the Italian NHS to compare two possible scenarios for managing pregnant women: women managed according to the Standard of Care screening (SoC) vs a cffDNA scenario, where Harmony Prenatal Test was introduced as a second line screening choice for women with an "at risk" result from SoC screening. RESULTS: The introduction of cffDNA as a second line screening test, conditional to a risk ≥ 1:1,000 from SoC screening, showed a 3% increase in the detection of trisomies, with a 71% decrease in the number of invasive tests performed. Total short-term costs (pregnancy management until childbirth) decreased by € 19 million (from € 84.5 to 65.5 million). CONCLUSION: The adoption of the Harmony Prenatal Test in women resulting at risk from SoC screening, implied a greater number of trisomies detection, together with a reduction of the healthcare costs.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Diagnóstico Pré-Natal / DNA / Síndrome de Down / Síndrome da Trissomia do Cromossomo 13 / Síndrome da Trissomía do Cromossomo 18 / Ácidos Nucleicos Livres Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies / Screening_studies Limite: Female / Humans / Pregnancy Idioma: En Revista: PLoS One Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Diagnóstico Pré-Natal / DNA / Síndrome de Down / Síndrome da Trissomia do Cromossomo 13 / Síndrome da Trissomía do Cromossomo 18 / Ácidos Nucleicos Livres Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies / Screening_studies Limite: Female / Humans / Pregnancy Idioma: En Revista: PLoS One Ano de publicação: 2019 Tipo de documento: Article